{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.3","upperLimit":"26.4","value":"16.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Duration of response was calculated from documentation of first response to date of progression in the subset of patients who responded. Patients without progression were censored at the date of last tumor evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression\n\nIntervention: Drug: melphalan 5mg/m\\^2 orally days 1-4 every 28 days until progression\n\nIntervention: Drug: prednisone 60mg/m\\^2, orally days 1-4 every 28 days until progression","id":"OG000","title":"Treatment (Lenalidomide, Melphalan, Prednisone)"}],"paramType":"MEDIAN","populationDescription":"Phase 2 Patients who had a response of PR or better are included in this analysis.","reportingStatus":"POSTED","timeFrame":"from first response to progression or death (up to 3 years)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}